{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:05:05Z","timestamp":1788915905022,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Viamet"},{"DOI":"10.13039\/100006931","name":"IMB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006931","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jsbmb.2016.04.021","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T16:10:19Z","timestamp":1462291819000},"page":"136-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature"],"prefix":"10.1016","volume":"163","author":[{"given":"Ian M.","family":"Bird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2016.04.021_bib0005","first-page":"533","article-title":"Endocrine cancer syndromes: an update","volume":"66","author":"Anik","year":"2014","journal-title":"Minerva Pediatr."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0010","first-page":"57","article-title":"Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance","volume":"6","author":"Tian","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0015","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.5b00760","article-title":"Oral selective estrogen receptor downregulators (SERDs): a Breakthrough endocrine therapy for Breast cancer","volume":"58","author":"McDonnell","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/IJWH.S69907","article-title":"Clinical utilities of aromatase inhibitors in breast cancer","volume":"7","author":"Chumsri","year":"2015","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-015-0147-z","article-title":"Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis","volume":"8","author":"Di Lauro","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1095\/biolreprod56.4.789","article-title":"The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals","volume":"56","author":"Conley","year":"1997","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0035","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.ejca.2014.06.004","article-title":"Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole","volume":"50","author":"Leibowitz-Amit","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2490-14-55","article-title":"Changing paradigms in management of metastatic castration resistant prostate cancer (mCRPC)","volume":"14","author":"Gupta","year":"2014","journal-title":"BMC Urol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0050","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7150\/ijbs.8844","article-title":"Beyond T and DHT\u2014novel steroid derivatives capable of wild type androgen receptor activation","volume":"10","author":"Mostaghel","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0055","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0060","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.urolonc.2015.03.021","article-title":"The development of abiraterone acetate for castration-resistant prostate cancer","volume":"33","author":"Grist","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jsbmb.2014.05.012","article-title":"Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology","volume":"145","author":"Labrie","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4103\/1008-682X.129133","article-title":"Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer","volume":"16","author":"Stein","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 inhibitors\u2013abiraterone C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Yin","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0080","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ecl.2015.02.001","article-title":"Development of adrenal cortex zonation","volume":"44","author":"Xing","year":"2015","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0090","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1074\/jbc.273.6.3158","article-title":"Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer","volume":"273","author":"Auchus","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2004-861548","article-title":"Variations in adrenal androgen production among (nonhuman) primates","volume":"22","author":"Conley","year":"2004","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/bj3320293","article-title":"Control of androgen biosynthesis in the human through the interaction of Arg347 and Arg358 of CYP17 with cytochrome b5","volume":"332","author":"Lee-Robichaud","year":"1998","journal-title":"Biochem. J"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0105","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1677\/JOE-08-0554","article-title":"Plasticity of the zona reticularis in the adult marmoset adrenal cortex: voyages of discovery in the New World","volume":"203","author":"Pattison","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ecl.2013.02.002","article-title":"Age-dependent and gender-dependent regulation of hypothalamic-adrenocorticotropic-adrenal axis","volume":"42","author":"Veldhuis","year":"2013","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0115","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ctrv.2013.03.003","article-title":"Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone","volume":"39","author":"Pia","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0120","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0125","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0130","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0135","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/0008-5472.CAN-09-2092","article-title":"Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer","volume":"70","author":"Hofland","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/pros.22967","article-title":"Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer","volume":"75","author":"Wu","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.2047-2927.2012.00026.x","article-title":"Development of prostate cancer in a patient with primary hypogonadism: intratumoural steroidogenesis in prostate cancer tissues","volume":"1","author":"Arai","year":"2013","journal-title":"Andrology"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jsbmb.2011.10.003","article-title":"Variation in 3beta-hydroxysteroid dehydrogenase activity and in pregnenolone supply rate can paradoxically alter androstenedione synthesis","volume":"128","author":"Nguyen","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jc.2011-2161","article-title":"The syndrome of 17,20 lyase deficiency","volume":"97","author":"Miller","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsbmb.2014.11.026","article-title":"The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1)","volume":"151","author":"Yoshimoto","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000134751","article-title":"Steroidogenic enzymes","volume":"13","author":"Miller","year":"2008","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0170","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1210\/jc.2013-3204","article-title":"21-Hydroxylase-derived steroids in follicles of nonobese women undergoing ovarian stimulation for in vitro fertilization (IVF) positively correlate with lipid content of luteinized granulosa cells (LGCs) as a source of cholesterol for steroid synthesis","volume":"99","author":"Amin","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0175","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1210\/jc.2013-1381","article-title":"Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women","volume":"98","author":"Fanelli","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0180","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1095\/biolreprod56.5.1077","article-title":"Localization of steroidogenic enzymes in macaque luteal tissue during the menstrual cycle and simulated early pregnancy: immunohistochemical evidence supporting the two-cell model for estrogen production in the primate corpus luteum","volume":"56","author":"Sanders","year":"1997","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000363107","article-title":"Novel insight into etiology: diagnosis and management of primary adrenal insufficiency","volume":"82","author":"Malikova","year":"2014","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0190","series-title":"Classical & Nonclassical Congenital Adrenal Hyperplasia","first-page":"2000-","article-title":"21-Hydroxylase deficiency","author":"New","year":"2006"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0195","first-page":"188","article-title":"Consensus statement on 21-hydroxylase deficiency from the european society for paediatric endocrinology and the lawson wilkins pediatric endocrine society","volume":"58","author":"Clayton","year":"2002","journal-title":"Horm. Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0200","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/0004563214529748","article-title":"17-Hydroxyprogesterone in children: adolescents and adults","volume":"51","author":"Honour","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0205","first-page":"215","article-title":"Diagnosis of late-onset congenital adrenal hyperplasia in clinical practice: current evaluation","volume":"39","author":"Sahmay","year":"2014","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10897-012-9508-8","article-title":"Prenatal treatment of congenital adrenal hyperplasia-not standard of care","volume":"21","author":"Witchel","year":"2012","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0215","doi-asserted-by":"crossref","first-page":"33838","DOI":"10.1074\/jbc.M114.608919","article-title":"Catalytically relevant electrostatic interactions of cytochrome P450c17 (CYP17A1) and cytochrome b5","volume":"289","author":"Peng","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0220","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1021\/bi300895w","article-title":"Minor activities and transition state properties of the human steroid hydroxylases cytochromes P450c17 and P450c21, from reactions observed with deuterium-labeled substrates","volume":"51","author":"Yoshimoto","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0225","doi-asserted-by":"crossref","first-page":"18939","DOI":"10.1016\/S0021-9258(19)47248-7","article-title":"Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase","volume":"264","author":"Agarwal","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0230","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1210\/jc.2011-2328","article-title":"Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: regulation of expression and association with ACTH responsiveness","volume":"97","author":"Hofland","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0235","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mce.2015.02.005","article-title":"Dynamics of adrenal glucocorticoid steroidogenesis in health and disease","volume":"408","author":"Spiga","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1210\/me.2009-0283","article-title":"Minireview: the melanocortin 2 receptor accessory proteins","volume":"24","author":"Webb","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0245","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archpsyc.1989.01810070067011","article-title":"Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pretreated with metyrapone","volume":"46","author":"Lisansky","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0250","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/07435809809032692","article-title":"The molecular basis of isolated 17,20 lyase deficiency","volume":"24","author":"Miller","year":"1998","journal-title":"Endocr. Res."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/FPC.0b013e3282fad38a","article-title":"Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes","volume":"18","author":"Schulze","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0889-8529(08)70021-5","article-title":"The genetics, pathophysiology, and management of human deficiencies of P450c17","volume":"30","author":"Auchus","year":"2001","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4158\/EP14474.RA","article-title":"The classic and nonclassic concenital adrenal hyperplasias","volume":"21","author":"Auchus","year":"2015","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0270","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/aje\/kwh287","article-title":"CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review","volume":"160","author":"Sharp","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000321221","article-title":"Clinical and biochemical consequences of p450 oxidoreductase deficiency","volume":"20","author":"Fluck","year":"2011","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000134826","article-title":"P450 oxidoreductase deficiency\u2014a new form of congenital adrenal hyperplasia","volume":"13","author":"Fluck","year":"2008","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0285","doi-asserted-by":"crossref","first-page":"E465","DOI":"10.1210\/jc.2011-2413","article-title":"A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true isolated 17,20 lyase deficiency","volume":"97","author":"Idkowiak","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0290","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.fertnstert.2013.11.011","article-title":"Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase\/17,20-lyase deficiency and isolated 17 20-lyase deficiency","volume":"101","author":"Marsh","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0295","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2265.2009.03607.x","article-title":"Identification of steroid biosynthetic defects in genotype-proven heterozygous individuals for 17alpha-hydroxylase\/17,20-lyase deficiency","volume":"72","author":"Qiao","year":"2010","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1590\/S0004-27302010000800008","article-title":"Six new cases confirm the clinical molecular profile of complete combined 17alpha-hydroxylase\/17,20-lyase deficiency in Brazil","volume":"54","author":"Belgini","year":"2010","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0305","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1590\/S0004-27302010000900009","article-title":"Distinctive profile of the 17-hydroxylase and 17,20-lyase activities revealed by urinary steroid metabolomes of patients with CYP17 deficiency","volume":"54","author":"Neres","year":"2010","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0310","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1210\/jc.2001-011880","article-title":"Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency","volume":"87","author":"Van Den Akker","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11306-013-0558-1","article-title":"Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia","volume":"10","author":"Hicks","year":"2014","journal-title":"Metabolomics"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4137\/CMRH.S14036","article-title":"Selective inhibition of steroidogenic enzymes by ketoconazole in rat ovary cells","volume":"8","author":"Gal","year":"2014","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0325","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1530\/JOE-12-0310","article-title":"Fluconazole inhibits human adrenocortical steroidogenesis in vitro","volume":"215","author":"van der Pas","year":"2012","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0330","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17 abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0335","doi-asserted-by":"crossref","DOI":"10.1038\/nrurol.2015.131","article-title":"Pharmacology: how abiraterone works","volume":"12","author":"Thoma","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0340","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pros.23014","article-title":"Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone","volume":"75","author":"Conteduca","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0345","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700) a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0355","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0360","article-title":"Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide","author":"Bambury","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0365","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.3390\/ijms140713958","article-title":"Recent progress in pharmaceutical therapies for castration-resistant prostate cancer","volume":"14","author":"Yin","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0370","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0375","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.12.021","article-title":"CYP17A1 inhibitors in castration-resistant prostate cancer","volume":"95","author":"Gomez","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0380","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.steroids.2011.06.002","article-title":"Synthesis and biological evaluations of putative metabolically stable analogs of VN\/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN\/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model","volume":"76","author":"Bruno","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0385","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0390","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"DeVore","year":"2012","journal-title":"Nature"},{"issue":"28\u201338","key":"10.1016\/j.jsbmb.2016.04.021_bib0395","first-page":"e25","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS consensus workshop group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0400","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/er.2015-1018","article-title":"Scientific statement on the diagnostic criteria epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome","volume":"36","author":"Dumesic","year":"2015","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0405","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4158\/EP15748.DSC","article-title":"American association of clinical endocrinologists american college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary Syndrome\u2014Part 1","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0410","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/JOE-12-0183","article-title":"The steroid metabolome of adrenarche","volume":"214","author":"Rege","year":"2012","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0415","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1677\/JOE-09-0127","article-title":"Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence","volume":"203","author":"Hui","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2016.04.021_bib0420","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1369\/jhc.2008.951384","article-title":"Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system","volume":"56","author":"Azzarello","year":"2008","journal-title":"J. Histochem. Cytochem."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076016301297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076016301297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:53:01Z","timestamp":1760745181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076016301297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":84,"alternative-id":["S0960076016301297"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2016.04.021","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2016.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}